UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Mark One)

For the quarterly period ended January 31, 2015

or

For the transition period from ______to______.

Commission File Number: 000-55330

LIGHTLAKE THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

(212) 829-5546

(Registrant’s telephone number, including area code)

96-98 Baker Street, First Floor, London, England W1U 6TJ

44 (0) 203 617 8739

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.:

Large Accelerated Filer  ¨ Accelerated Filer  ¨ Non-Accelerated Filer  ¨ (Do not check if a smaller reporting company) Smaller Reporting Company  x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock: As of March 12, 2015, there were 1,827,562 shares, $0.001 par value per share, of common stock outstanding.

EXPLANATORY NOTE

Lightlake Therapeutics Inc. (also referred to as the “Company,” “we,” or “our”) is filing this amendment (Amendment No. 1) to the Quarterly Report on Form 10-Q for the quarter ended January 31, 2015 (the “January 2015 Form 10-Q”), originally filed with the Securities and Exchange Commission on March 17, 2015, for the sole purpose of providing revised copies of Exhibits 10.1 and 10.2 to restore certain information that was previously omitted from Exhibits 10.1 and 10.2 pursuant to a request for confidential treatment. All other items of the January 2015 Form 10-Q are unaffected by the change described above and have been omitted from this Amendment No. 1.

The Exhibit Index listed under Item 6 of Part II of the January 2015 Form 10-Q is hereby amended such that Exhibits 10.1 and 10.2 are replaced in their entirety by the documents attached as exhibits to this Amendment No. 1, which are hereby included as exhibits to the January 2015 Form 10-Q.

+ Confidential Treatment Requested.  Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

* Filed herewith.

** Previously furnished.

*** Previously filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.